Croft-Leominster’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Croft-Leominster’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-15,000	Closed	-$101K	–	218
2014 Q2	$101K	Sell	15,000 -5,000	-25%	-$31.8K	0.02%	188
2014 Q1	$144K	Sell	20,000 -4,000	-17%	-$23.7K	0.02%	183
2013 Q4	$90K	Sell	24,000 -10,000	-29%	-$38.7K	0.01%	200
2013 Q3	$114K	Buy	+34,000	New	+$118K	0.02%	179

Other funds holding NWBO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Croft-Leominster's NWBO Position: Q3 2014 in Review

Croft-Leominster sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2014, closing a stake of 15,000 shares — an estimated $101K sold.

Croft-Leominster first reported a position in NWBO in Q3 2013 and held it in 4 quarters. The position peaked at $144K in Q1 2014. 71 funds tracked by Wall St. Rank hold NWBO as of Q3 2014.

Croft-Leominster reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2014 after selling out during the quarter.
Croft-Leominster sold 15,000 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2014, an estimated $101K.
Croft-Leominster first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2013 and held it in 4 quarters.
Croft-Leominster's Northwest Biotherapeutics, Inc. Common stock position peaked at $144K in Q1 2014.
71 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2014.

Based on Croft-Leominster's 13F filing for Q3 2014, filed 14 Nov 2014.